


**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound of formula I



wherein

W is N or CR<sub>2</sub>;

X is N or CR<sub>9</sub>;

Y is N or CR<sub>10</sub>;

Z is N or CR<sub>11</sub>;

Q is N or CR<sub>12</sub> with the proviso that at least one and not more than two of X, Y, Z and Q must be N;

R<sub>1</sub> is an optionally substituted C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, aryl, or heteroaryl group or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;

R<sub>2</sub> is H, halogen, or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, aryl or heteroaryl group each optionally substituted;

R<sub>3</sub> and R<sub>4</sub> are each independently H or an optionally substituted C<sub>1</sub>-C<sub>6</sub>alkyl group;

R<sub>5</sub> is H or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

R<sub>6</sub> is a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl or C<sub>2</sub>-C<sub>6</sub>alkynyl group each optionally substituted;

R<sub>7</sub> and R<sub>8</sub> are each independently H or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl or C<sub>2</sub>-C<sub>6</sub>alkynyl group each optionally substituted;

m and n are each independently 0 or an integer of 1, 2 or 3;

p is 0 or an integer of 1 or 2;

R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub> and R<sub>12</sub> are each independently H, halogen, CN, OCO<sub>2</sub>R<sub>13</sub>, CO<sub>2</sub>R<sub>14</sub>, CONR<sub>15</sub>R<sub>16</sub>, SO<sub>x</sub>R<sub>17</sub>, NR<sub>18</sub>R<sub>19</sub>, OR<sub>20</sub>, COR<sub>21</sub> or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, aryl or heteroaryl group each optionally substituted;

R<sub>13</sub>, R<sub>14</sub>, R<sub>17</sub> and R<sub>21</sub> are each independently H or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

R<sub>15</sub>, R<sub>16</sub>, R<sub>18</sub> and R<sub>19</sub> are each independently H or an optionally substituted C<sub>1</sub>-C<sub>4</sub>alkyl group or R<sub>15</sub> and R<sub>16</sub> or R<sub>18</sub> and R<sub>19</sub> may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, NR<sub>22</sub> or SO<sub>q</sub>;

R<sub>20</sub> is a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

x and q are each independently 0 or an integer of 1 or 2; and

R<sub>22</sub> is H or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, cycloheteroalkyl, aryl or heteraryl group each optionally substituted; or


the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

2. (Original) The compound according to claim 1 wherein n is 0 or 1.
3. (Original) The compound according to claim 1 wherein R<sub>5</sub> is H or methyl.
4. (Original) The compound according to claim 1 wherein R<sub>1</sub> is an optionally substituted phenyl, thienyl or imidazothiazolyl group.
5. (Original) The compound according to claim 2 wherein p is 0 or 1.
6. (Original) The compound according to claim 2 wherein m is 0.
7. (Original) The compound according to claim 5 wherein the piperidinyl group is attached in the 3-position of the piperidine ring or the pyrrolidinyl group is attached in the 2-position of the pyrrolidine ring.
8. (Original) The compound according to claim 7 wherein R<sub>5</sub> is H or methyl and R<sub>1</sub> is an optionally substituted phenyl, thienyl or imidazothiazolyl group.
9. (Currently Amended) The compound according to claim 1 selected from the group consisting of:  
3-(phenylsulfonyl)-1-[(2R)-pyrrolidin-2-ylmethyl]-1H-pyrrolo[2,3-b]pyridine;  
3-(phenylsulfonyl)-1-[(2S)-pyrrolidin-2-ylmethyl]-1H-pyrrolo[2,3-b]pyridine;  
3-[(4-methylphenyl)sulfonyl]-1-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;  
6-bromo-3-(phenylsulfonyl)-1-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-c]pyridine;

~~4-chloro-3-(phenylsulfonyl)-1-(piperidin-4-ylmethyl)-1H-pyrazolo[4,3-b]pyridine;~~  
~~7-methoxy-3-(phenylsulfonyl)-1-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-c]pyridine;~~  
~~6-hydroxy-3-(phenylsulfonyl)-1-(piperidin-4-ylmethyl)-1H-pyrrolo[3,2-b]pyridine;~~  
~~6-chloro-3-[(4-fluorophenyl)sulfonyl]-1-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-c]pyridine;~~  
~~6-fluoro-3-[(3-fluorophenyl)sulfonyl]-1-(piperidin-4-ylmethyl)-1H-pyrrolo[3,2-b]pyridine;~~  
~~5-chloro-3-[(3-chlorophenyl)sulfonyl]-1-(piperidin-4-ylmethyl)-1H-pyrrolo[3,2-c]pyridine;~~  
~~3-[(2-chlorophenyl)sulfonyl]-6-fluoro-1-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-c]pyridine;~~  
~~3-[(2-fluorophenyl)sulfonyl]-6-methoxy-1-(piperidin-4-ylmethyl)-1H-pyrrolo[3,2-b]pyridine;~~  
~~4-chloro-3-(phenylsulfonyl)-1-(piperidin-3-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;~~  
~~7-methoxy-3-(phenylsulfonyl)-1-(piperidin-3-ylmethyl)-1H-pyrrolo[2,3-c]pyridine;~~  
~~6-hydroxy-3-(phenylsulfonyl)-1-(piperidin-3-ylmethyl)-1H-pyrrolo[3,2-b]pyridine;~~  
~~6-chloro-3-[(4-fluorophenyl)sulfonyl]-1-(piperidin-2-ylmethyl)-1H-pyrrolo[3,2-c]pyridine;~~  
~~6-fluoro-3-[(3-fluorophenyl)sulfonyl]-1-(piperidin-2-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;~~  
~~5-chloro-3-[(3-chlorophenyl)sulfonyl]-1-(piperidin-2-ylmethyl)-1H-pyrrolo[2,3-c]pyridine;~~  
~~3-[(2-chlorophenyl)sulfonyl]-6-fluoro-1-(piperidin-2-ylmethyl)-1H-pyrrolo[3,2-b]pyridine;~~  
~~3-[(2-fluorophenyl)sulfonyl]-6-methoxy-1-(piperidin-2-ylmethyl)-1H-pyrrolo[3,2-c]pyridine;~~  
~~3-(phenylsulfonyl)-1-(piperidin-4-ylmethyl)-1H-pyrazolo[4,3-b]pyridine;~~  
~~3-(phenylsulfonyl)-1-(piperidin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine;~~  
~~3-(phenylsulfonyl)-1-(piperidin-2-ylmethyl)-1H-pyrazolo[4,3-b]pyridine;~~  
~~3-(phenylsulfonyl)-1-(pyrrolidin-3-ylmethyl)-1H-pyrazolo[3,4-c]pyridine;~~  
~~3-(phenylsulfonyl)-1-(pyrrolidin-2-ylmethyl)-1H-pyrazolo[3,4-b]pyridine;~~  
~~6-bromo-3-(phenylsulfonyl)-1-(pyrrolidin-3-ylmethyl)-1H-pyrrolo[3,2-c]pyridine;~~  
~~4-chloro-2-methyl-3-(phenylsulfonyl)-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;~~  
~~7-methoxy-3-(phenylsulfonyl)-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[2,3-c]pyridine;~~  
~~6-hydroxy-3-(phenylsulfonyl)-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[3,2-b]pyridine;~~  
~~1-(piperidin-2-ylmethyl)-3-(2-pyridinylsulfonyl)-1H-pyrrolo[3,2-c]pyridine;~~  
~~1-(piperidin-3-ylmethyl)-3-(2-pyridinylsulfonyl)-1H-pyrrolo[2,3-b]pyridine;~~  
~~3-(2-pyridinylsulfonyl)-1-(pyrrolidin-3-ylmethyl)-1H-pyrrolo[2,3-c]pyridine;~~  
~~1-(piperidin-3-ylmethyl)-3-(2-thienylsulfonyl)-1H-pyrazolo[4,3-b]pyridine;~~  
~~1-(piperidin-2-ylmethyl)-3-(2-thienylsulfonyl)-1H-pyrazolo[4,3-b]pyridine;~~  
~~3-(phenylsulfonyl)-1-piperidin-3-yl-1H-pyrazolo[4,3-b]pyridine;~~  
~~3-[(2-fluorophenyl)sulfonyl]-1-pyrrolidin-3-yl-1H-pyrazolo[4,3-b]pyridine;~~  
~~1-(1-methylpiperidin-4-yl)-3-(phenylsulfonyl)-1H-pyrazolo[4,3-b]pyridine;~~  
~~1-(1-phenethylpyrrolidin-3-yl)-3-(phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridine;~~  
~~1-piperidin-4-yl-3-(2-pyridylsulfonyl)-1H-pyrrolo[2,3-c]pyridine;~~  
~~1-piperidin-3-yl-3-(2-thienylsulfonyl)-1H-pyrrolo[3,2-b]pyridine;~~  
~~1-pyrrolidin-3-yl-3-(3-thienylsulfonyl)-1H-pyrrolo[3,2-b]pyridine;~~  
~~1-[(1-benzylpyrrolidin-2-yl)methyl]-3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine;~~

3-(phenylsulfonyl)-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;  
1-[(1-benzylpyrrolidin-2-yl)methyl]-3-(3-fluorophenylsulfonyl)-1H-pyrrolo[2,3-b]-pyridine;  
3-(3-fluorophenylsulfonyl)-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;  
1-[(1-benzylpyrrolidin-2-yl)methyl]-3-(3-chlorophenylsulfonyl)-1H-pyrrolo[2,3-b]-pyridine;  
3-(3-chlorophenylsulfonyl)-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;  
3-(3-chlorophenylsulfonyl)-1-[(1-methylpyrrolidin-2-yl)methyl]-1H-pyrrolo[2,3-b]pyridine;  
3-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;  
3-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1-(1-methylpiperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine;  
3-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine;  
3-[(6-chlorothien-2-yl)sulfonyl]-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;  
the stereoisomers thereof; and  
the pharmaceutically acceptable salts thereof.

10. (Withdrawn) A method for the treatment of a central nervous system disorder related to or affected by the 5-HT<sub>6</sub> receptor in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I



wherein

W is N or CR<sub>2</sub>;

X is N or CR<sub>9</sub>;

Y is N or CR<sub>10</sub>;

Z is N or CR<sub>11</sub>;

Q is N or CR<sub>12</sub> with the proviso that at least one and not more than two of X, Y, Z and Q must be N;

R<sub>1</sub> is an optionally substituted C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, aryl, or heteroaryl group or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;

R<sub>2</sub> is H, halogen, or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, aryl or heteroaryl group each optionally substituted;

R<sub>3</sub> and R<sub>4</sub> are each independently H or an optionally substituted C<sub>1</sub>-C<sub>6</sub>alkyl group;  
R<sub>5</sub> is H or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;  
R<sub>6</sub> is a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl or C<sub>2</sub>-C<sub>6</sub>alkynyl group each optionally substituted;  
R<sub>7</sub> and R<sub>8</sub> are each independently H or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl or C<sub>2</sub>-C<sub>6</sub>alkynyl group each optionally substituted;  
m and n are each independently 0 or an integer of 1, 2 or 3;  
p is 0 or an integer of 1 or 2;  
R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub> and R<sub>12</sub> are each independently H, halogen, CN, OCO<sub>2</sub>R<sub>13</sub>, CO<sub>2</sub>R<sub>14</sub>, CONR<sub>15</sub>R<sub>16</sub>, SO<sub>x</sub>R<sub>17</sub>, NR<sub>18</sub>R<sub>19</sub>, OR<sub>20</sub>, COR<sub>21</sub> or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, aryl or heteroaryl group each optionally substituted;  
R<sub>13</sub>, R<sub>14</sub>, R<sub>17</sub> and R<sub>21</sub> are each independently H or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;  
R<sub>15</sub>, R<sub>16</sub>, R<sub>18</sub> and R<sub>19</sub> are each independently H or an optionally substituted C<sub>1</sub>-C<sub>4</sub>alkyl group or R<sub>15</sub> and R<sub>16</sub> or R<sub>18</sub> and R<sub>19</sub> may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, NR<sub>22</sub> or SO<sub>q</sub>;  
R<sub>20</sub> is a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;  
x and q are each independently 0 or an integer of 1 or 2; and  
R<sub>22</sub> is H or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; or  
the stereoisomers thereof or the pharmaceutically acceptable salts thereof.


11. (Withdrawn) The method according to claim 10 wherein said disorder is a motor disorder, anxiety disorder or cognitive disorder.

12. (Withdrawn) The method according to claim 10 wherein said disorder is a neurodegenerative disorder.

13. (Withdrawn) The method according to claim 11 wherein said disorder is selected from the group consisting of: attention deficit disorder; obsessive compulsive disorder; and withdrawal from drug, alcohol or nicotine addiction.

14. (Withdrawn) The method according to claim 12 wherein said disorder is stroke or head trauma.

15. (Currently Amended) A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I



wherein

W is ~~N~~ or CR<sub>2</sub>;

X is N or CR<sub>9</sub>;

Y is N or CR<sub>10</sub>;

Z is N or CR<sub>11</sub>;

Q is N or CR<sub>12</sub> with the proviso that at least one and not more than two of X, Y, Z and Q must be N;

R<sub>1</sub> is an optionally substituted C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, aryl, or heteroaryl group or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;

R<sub>2</sub> is H, halogen, or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, aryl or heteroaryl group each optionally substituted;

R<sub>3</sub> and R<sub>4</sub> are each independently H or an optionally substituted C<sub>1</sub>-C<sub>6</sub>alkyl group;

R<sub>5</sub> is H or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

R<sub>6</sub> is a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl or C<sub>2</sub>-C<sub>6</sub>alkynyl group each optionally substituted;

R<sub>7</sub> and R<sub>8</sub> are each independently H or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl or C<sub>2</sub>-C<sub>6</sub>alkynyl group each optionally substituted;

m and n are each independently 0 or an integer of 1, 2 or 3;

p is 0 or an integer of 1 or 2;

R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub> and R<sub>12</sub> are each independently H, halogen, CN, OCO<sub>2</sub>R<sub>13</sub>, CO<sub>2</sub>R<sub>14</sub>, CONR<sub>15</sub>R<sub>16</sub>, SO<sub>x</sub>R<sub>17</sub>, NR<sub>18</sub>R<sub>19</sub>, OR<sub>20</sub>, COR<sub>21</sub> or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, aryl or heteroaryl group each optionally substituted;

R<sub>13</sub>, R<sub>14</sub>, R<sub>17</sub> and R<sub>21</sub> are each independently H or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

R<sub>15</sub>, R<sub>16</sub>, R<sub>18</sub> and R<sub>19</sub> are each independently H or an optionally substituted C<sub>1</sub>-C<sub>4</sub>alkyl group or R<sub>15</sub> and R<sub>16</sub> or R<sub>18</sub> and R<sub>19</sub> may be taken together with the atom to

which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, NR<sub>22</sub> or SO<sub>q</sub>;

R<sub>20</sub> is a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

x and q are each independently 0 or an integer of 1 or 2; and

R<sub>22</sub> is H or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, cycloheteroalkyl, aryl or heteraryl group each optionally substituted; or

the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

16. (Original) The composition according to claim 15 having a formula I compound wherein n is 0 or 1.

17. (Original) The composition according to claim 16 having a formula I compound wherein R<sub>1</sub> is an optionally substituted phenyl, thienyl or imidazothiazolyl group and R<sub>5</sub> is H or methyl.

18. (Original) The composition according to claim 17 having a formula I compound wherein p is 0 or 1 and the piperidinyl group is attached in the 3-position of the piperidine ring or the pyrrolidinyl group is attached in the 2-position of the pyrrolidine ring.

19. (Currently Amended) The composition according to claim 15 having a formula I compound selected from the group consisting of:


3-(phenylsulfonyl)-1-[(2R)-pyrrolidin-2-ylmethyl]-1H-pyrrolo[2,3-b]pyridine;  
3-(phenylsulfonyl)-1-[(2S)-pyrrolidin-2-ylmethyl]-1H-pyrrolo[2,3-b]pyridine;  
3-[(4-methylphenyl)sulfonyl]-1-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;  
6-bromo-3-(phenylsulfonyl)-1-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-c]pyridine;  
~~4-chloro-3-(phenylsulfonyl)-1-(piperidin-4-ylmethyl)-1H-pyrazolo[4,3-b]pyridine;~~  
7-methoxy-3-(phenylsulfonyl)-1-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-c]pyridine;  
6-hydroxy-3-(phenylsulfonyl)-1-(piperidin-4-ylmethyl)-1H-pyrrolo[3,2-b]pyridine;  
6-chloro-3-[(4-fluorophenyl)sulfonyl]-1-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-c]pyridine;  
6-fluoro-3-[(3-fluorophenyl)sulfonyl]-1-(piperidin-4-ylmethyl)-1H-pyrrolo[3,2-b]pyridine;  
5-chloro-3-[(3-chlorophenyl)sulfonyl]-1-(piperidin-4-ylmethyl)-1H-pyrrolo[3,2-c]pyridine;  
3-[(2-chlorophenyl)sulfonyl]-6-fluoro-1-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-c]pyridine;  
3-[(2-fluorophenyl)sulfonyl]-6-methoxy-1-(piperidin-4-ylmethyl)-1H-pyrrolo[3,2-b]pyridine;  
4-chloro-3-(phenylsulfonyl)-1-(piperidin-3-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;  
7-methoxy-3-(phenylsulfonyl)-1-(piperidin-3-ylmethyl)-1H-pyrrolo[2,3-c]pyridine;  
6-hydroxy-3-(phenylsulfonyl)-1-(piperidin-3-ylmethyl)-1H-pyrrolo[3,2-b]pyridine;  
6-chloro-3-[(4-fluorophenyl)sulfonyl]-1-(piperidin-2-ylmethyl)-1H-pyrrolo[3,2-c]pyridine;

6-fluoro-3-[(3-fluorophenyl)sulfonyl]-1-(piperidin-2-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;  
5-chloro-3-[(3-chlorophenyl)sulfonyl]-1-(piperidin-2-ylmethyl)-1H-pyrrolo[2,3-c]pyridine;  
3-[(2-chlorophenyl)sulfonyl]-6-fluoro-1-(piperidin-2-ylmethyl)-1H-pyrrolo[3,2-b]pyridine;  
3-[(2-fluorophenyl)sulfonyl]-6-methoxy-1-(piperidin-2-ylmethyl)-1H-pyrrolo[3,2-c]pyridine;  
~~3-(phenylsulfonyl)-1-(piperidin-4-ylmethyl)-1H-pyrazolo[4,3-b]pyridine;~~  
~~3-(phenylsulfonyl)-1-(piperidin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine;~~  
~~3-(phenylsulfonyl)-1-(piperidin-2-ylmethyl)-1H-pyrazolo[4,3-b]pyridine;~~  
~~3-(phenylsulfonyl)-1-(pyrrolidin-3-ylmethyl)-1H-pyrazolo[3,4-c]pyridine;~~  
~~3-(phenylsulfonyl)-1-(pyrrolidin-2-ylmethyl)-1H-pyrazolo[3,4-b]pyridine;~~  
6-bromo-3-(phenylsulfonyl)-1-(pyrrolidin-3-ylmethyl)-1H-pyrrolo[3,2-c]pyridine;  
4-chloro-2-methyl-3-(phenylsulfonyl)-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;  
7-methoxy-3-(phenylsulfonyl)-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[2,3-c]pyridine;  
6-hydroxy-3-(phenylsulfonyl)-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[3,2-b]pyridine;  
1-(piperidin-2-ylmethyl)-3-(2-pyridinylsulfonyl)-1H-pyrrolo[3,2-c]pyridine;  
1-(piperidin-3-ylmethyl)-3-(2-pyridinylsulfonyl)-1H-pyrrolo[2,3-b]pyridine;  
3-(2-pyridinylsulfonyl)-1-(pyrrolidin-3-ylmethyl)-1H-pyrrolo[2,3-c]pyridine;  
~~1-(piperidin-3-ylmethyl)-3-(2-thienylsulfonyl)-1H-pyrazolo[4,3-b]pyridine;~~  
~~1-(piperidin-2-ylmethyl)-3-(2-thienylsulfonyl)-1H-pyrazolo[4,3-b]pyridine;~~  
~~3-(phenylsulfonyl)-1-piperidin-3-yl-1H-pyrazolo[4,3-b]pyridine;~~  
~~3-[(2-fluorophenyl)sulfonyl]-1-pyrrolidin-3-yl-1H-pyrazolo[4,3-b]pyridine;~~  
~~1-(1-methylpiperidin-4-yl)-3-(phenylsulfonyl)-1H-pyrazolo[4,3-b]pyridine;~~  
1-(1-phenethylpyrrolidin-3-yl)-3-(phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridine;  
1-piperidin-4-yl-3-(2-pyridylsulfonyl)-1H-pyrrolo[2,3-c]pyridine;  
1-piperidin-3-yl-3-(2-thienylsulfonyl)-1H-pyrrolo[3,2-b]pyridine;  
1-pyrrolidin-3-yl-3-(3-thienylsulfonyl)-1H-pyrrolo[3,2-b]pyridine;  
1-[(1-benzylpyrrolidin-2-yl)methyl]-3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine;  
3-(phenylsulfonyl)-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;  
1-[(1-benzylpyrrolidin-2-yl)methyl]-3-(3-fluorophenylsulfonyl)-1H-pyrrolo[2,3-b]-pyridine;  
3-(3-fluorophenylsulfonyl)-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;  
1-[(1-benzylpyrrolidin-2-yl)methyl]-3-(3-chlorophenylsulfonyl)-1H-pyrrolo[2,3-b]-pyridine;  
3-(3-chlorophenylsulfonyl)-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;  
3-(3-chlorophenylsulfonyl)-1-[(1-methylpyrrolidin-2-yl)methyl]-1H-pyrrolo[2,3-b]pyridine;  
3-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;  
3-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1-(1-methylpiperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine;  
3-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine;



3-[(6-chlorothien-2-yl)sulfonyl]-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;  
the stereoisomers thereof; and  
the pharmaceutically acceptable salts thereof.

20. (Withdrawn) A process for the preparation of a compound of formula I



wherein

W is N or CR<sub>2</sub>;

X is N or CR<sub>9</sub>;

Y is N or CR<sub>10</sub>;

Z is N or CR<sub>11</sub>;

Q is N or CR<sub>12</sub> with the proviso that at least one and not more than two of X, Y, Z and Q must be N;

R<sub>1</sub> is an optionally substituted C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, aryl, or heteroaryl group or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;

R<sub>2</sub> is H, halogen, or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, aryl or heteroaryl group each optionally substituted;

R<sub>3</sub> and R<sub>4</sub> are each independently H or an optionally substituted C<sub>1</sub>-C<sub>6</sub>alkyl group;

R<sub>5</sub> is H or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

R<sub>6</sub> is a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl or C<sub>2</sub>-C<sub>6</sub>alkynyl group each optionally substituted;

R<sub>7</sub> and R<sub>8</sub> are each independently H or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl or C<sub>2</sub>-C<sub>6</sub>alkynyl group each optionally substituted;

m and n are each independently 0 or an integer of 1, 2 or 3;

p is 0 or an integer of 1 or 2;

R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub> and R<sub>12</sub> are each independently H, halogen, CN, OCO<sub>2</sub>R<sub>13</sub>, CO<sub>2</sub>R<sub>14</sub>, CONR<sub>15</sub>R<sub>16</sub>, SO<sub>x</sub>R<sub>17</sub>, NR<sub>18</sub>R<sub>19</sub>, OR<sub>20</sub>, COR<sub>21</sub> or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, aryl or heteroaryl group each optionally substituted;

R<sub>13</sub>, R<sub>14</sub>, R<sub>17</sub> and R<sub>21</sub> are each independently H or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;


R<sub>15</sub>, R<sub>16</sub>, R<sub>18</sub> and R<sub>19</sub> are each independently H or an optionally substituted C<sub>1</sub>-C<sub>4</sub>alkyl group or R<sub>15</sub> and R<sub>16</sub> or R<sub>18</sub> and R<sub>19</sub> may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, NR<sub>22</sub> or SO<sub>q</sub>;

R<sub>20</sub> is a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;

x and q are each independently 0 or an integer of 1 or 2; and


R<sub>22</sub> is H or a C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, cycloheteroalkyl, aryl or heteraryl group each optionally substituted

which process comprises reacting a compound of formula II



(II)

wherein W, X, Y, Z and Q are described hereinabove with a protected azacyclic compound of formula III



(III)

wherein L represents a leaving group; P represents a protecting group and R<sub>3</sub>, R<sub>4</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub>, n, m and p are as described hereinabove in the presence of a first base to give the protected amine of formula I; and deprotecting said amine to give the compound of formula I wherein R<sub>5</sub> is H optionally alkylating said formula I compound with a compound, R<sub>5</sub>-L', wherein L' is a leaving group in the presence of a second base.